Dr. Glytsou is part of a collaborative review in Nature Reviews Clinical Oncology highlighting the transformative potential of BH3 mimetics in AML therapy and the ongoing efforts to understand and circumvent therapy resistance.
https://www.nature.com/articles/s41571-025-01068-0